Dermapharm Reports Revenue Decline, EBITDA Improvement in 2025

In its preliminary results for 2025, Dermapharm Holding SE posted a decrease in consolidated revenue to EUR 1,165.0 million, a 1.3% drop, primarily due to the phase-out of low-margin products in the "Parallel import business" segment. In contrast, the company saw a rise in adjusted consolidated EBITDA by 2.9% to EUR 324.8 million, resulting in a margin improvement to 27.9%.

The earnings uplift is attributed to structural adjustments, despite revenue setbacks in some sectors. The "Branded pharmaceuticals" segment showed solid organic growth, supported by a robust product portfolio, while other healthcare products maintained stable revenue despite currency impacts.

Dermapharm's strategy to streamline its portfolio, focusing on high-margin products, affected its "Parallel import business" earnings, underlining the company's aim for sustainable profitability.